Orange Grove Bio

Orange Grove Bio (OGB) operates as a preclinical drug investment and development platform, translating early-stage academic research into novel therapeutics. The company strategically targets unmet medical needs within cancer, autoimmune, and inflammatory diseases. OGB provides critical capital and integrated research and development capabilities, accelerating nascent drug programs through foundational stages.

Founded in 2019 and headquartered in Cincinnati, Ohio, Orange Grove Bio was established to bridge the translational gap between academic discoveries and viable drug candidates. The firm developed a specialized platform offering strategic investment and scientific expertise, systematically nurturing promising research to de-risk and advance new therapies.

OGB's efforts benefit patients by accelerating new treatment options for severe conditions. The company's vision centers on enhancing drug discovery and development efficiency, aiming to reduce costs and expedite groundbreaking medicines. Orange Grove Bio remains dedicated to fostering a robust pipeline of therapeutic assets, significantly improving patient quality of life.